Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics Inc.

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Travere Therapeutics today and set a price target of $47.00. According to TipRa...

H.C. Wainwright Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX – Research Report) and Bo...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX)

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics, with a price target of $49.00. The com...

Guggenheim Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Travere Therapeutics ( ($TVTX) ) has issued an announcement. On January 13, 2026, Travere Therapeutics announced that the U.S. Food and Drug Admini...

FDA Extends Review Timeline for Travere’s FILSPARI sNDA

Shares in Travere Therapeutics ($TVTX) plunged over 33% on Tuesday after U.S. health watchdog extended its decision date for the biotech firm’s FIL...

Why Is Travere Therapeutics Stock (TVTX) Tumbling Today?

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Travere Therapeu...

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR)

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Travere Therapeutics today and set a price target of $42.00. According to TipRa...

Evercore ISI Remains a Buy on Travere Therapeutics (TVTX)

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Travere Therapeutics, with a price target of $40.00. Bansal co...

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Travere Therapeutics today and set a price target of $47.00. Zemansky ...

Market Cap	$2.69B	P/E Ratio	N/A
52W High	$42.13	52W Low	$12.91
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-10.7%	52W Position	67.8%
Overall Score	48	Value Score	40
Quality Score	55	Technical Score	50

EPS Current Est	$-0.32	EPS Next Est	$0.57
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TVTX	$32.73	-1.10%	1.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TVTX	$32.73	-1.1%	1.20M
3
4
5
6

TVTX

TVTX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Travere Therapeutics Inc. Data in Excel

Get Travere Therapeutics Inc. Data in Excel